EU/3/13/1150

About

On 17 July 2013, orphan designation (EU/3/13/1150) was granted by the European Commission to MedImmune Ltd, United Kingdom, for moxetumomab pasudotox for the treatment of B-lymphoblastic leukaemia / lymphoma.

The sponsorship was transferred to AstraZeneca AB, Sweden, in January 2019.

Key facts

Active substance
Moxetumomab pasudotox
Disease / condition
Treatment of B-lymphoblastic leukaemia/lymphoma
Date of first decision
17/07/2013
Outcome
Positive
EU designation number
EU/3/13/1150

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

AstraZeneca AB
Södertälje SE 151 85
Sweden
Tel: + 46 8 553 260 00
E-mail: EuropeanMedicalInformation@astrazeneca.com

 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating